April 16, 2008

 

RFCL to acquire Bremer Pharma

 

Press Release

 

 

RFCL announced its first global acquisition with the recent agreement to acquire Bremer Pharma, and this move will put the company among the top 25 global integrated veterinary healthcare companies by 2009.

 

The agreement is for the transfer of all key personnel, assets, brands and the name "Bremer Pharma", all contracts including exports. RFCL will gain a marketing foothold in the city of Bremerhaven, near Hamburg and a state-of-the-art manufacturing base in Warburg-Scherfede with a processing capacity of nearly 663,000 litres of liquids per annum per shift, nearly 1,032 tonnes of solids per annum per shift and 1.5 million vials of Sterile solutions per annum per shift.

 

Bremer Pharma brings along an extensive quality assurance system that is certified and based on the requirements of the EDQM guidelines, guaranteeing transparency and optimisation of all workflows in the organization.

 

This acquisition will propel RFCL's Animal Healthcare business onto the global map. The healthcare business is estimated to achieve a turnover of Rs 900 million (US$22.5 million) in fiscal year 2008, registering a growth of almost 22 percent over the previous year.

 

Combined with sales revenue of Bremer Pharma and Alved, RFCL's veterinary product portfolio will be in excess of Rs 1.6 billion (US$40 million).

 

This agreement will be the first step taken by RFCL to establish itself in the industry while giving the company a strategic platform to enter the EU and Middle East markets, according to Sushil Mehta, managing director of RFCL.

 

 

About RFCL
 

RFCL is 100 percent owned by ICICI Venture, India's largest private equity firm. RFCL focuses on in vitro diagnostics, animal healthcare, laboratory solutions and custom synthesis through its four strategic business units, namely, Diagnova, Vetnex, Rankem and Neosynth.

 

 

About Bremer Pharma GmbH
 

Bremer Pharma, a subsidiary of Marsing & Co Limited A/S, has been into research, manufacturing and supplying veterinary medical preparations including powders, tablets, solutions, suspensions and injectables for over 26 years, through a worldwide distribution network. It has 803 global registrations across the EU, Middle East, Asia and Africa.